Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
October 07, 2021 09:00 ET
|
Avalon GloboCare Corp.
Avalon and research partner, University of Natural Resources and Life Sciences (BOKU), in Vienna, Austria, co-develop a novel technology to efficiently synthesize and study previously difficult to...
Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30th
September 23, 2021 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today...
UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare
August 04, 2021 09:00 ET
|
Avalon GloboCare Corp.
PITTSBURGH, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp....
Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain Cancer
July 01, 2021 09:00 ET
|
Avalon GloboCare Corp.
Trial evaluating EphA2-targeted CAR T-cell therapy in recurrent glioblastoma, an urgent and significant unmet medical need with no standard of care treatment option Anti-EphA2 CAR-T therapy appears...
Avalon GloboCare CEO Provides Letter to Update Shareholders About Acquisition of SenlangBio
June 28, 2021 09:04 ET
|
Avalon GloboCare Corp.
Previously Announced Execution of Definitive Agreement to Acquire SenlangBio SenlangBio Generated Revenue of USD $1.2 Million for the Three Months Ended March 31, 2021 and Projects $5 Million to $7...
Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
June 14, 2021 09:00 ET
|
Avalon GloboCare Corp.
SenlangBio, a world-class cell therapy company, has developed a robust pipeline which includes 15 autologous and universal (“off-the-shelf”) CAR-T and CAR-γδT cell therapy candidates targeting...
Avalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit on June 17, 2021
June 11, 2021 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today...
Avalon GloboCare To Present Its S-Layer and QTY Code Breakthrough Technology Platforms at The Prestigious Annual World Stem Cell Summit
June 08, 2021 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today...
Avalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR™ Platform
March 29, 2021 09:25 ET
|
Avalon GloboCare Corp.
Development of FLASH-CAR™ RNA-based cellular therapies includes utilization of Avalon’s new Point-of-Care Modular Autonomous Processing System (PMAPsys™)First FLASH-CAR™ candidate, AVA-011, on-track...
Avalon GloboCare Expands Co-Development Program with MIT to Combat Cancer Metastasis
March 22, 2021 09:00 ET
|
Avalon GloboCare Corp.
Dual cutting edge technology approach using CRISPR-based genome editing and QTY code-based truncated chemokine receptors Expansion of co-development program with Dr. Shuguang Zhang at the...